|
|
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Sep 08, 2020 |
Title |
Elucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR/Cas9 screening and transcriptomics |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
The adenosine analogue remdesivir has emerged as a front-line antiviral treatment for SARS-CoV-2, with preliminary evidence that it reduces the duration and severity of illness. As clinical trials are ongoing, the full side effect profile of remdesivir is not yet known. Prior clinical studies have identified adverse events, and remdesivir has been shown to inhibit mitochondrial RNA polymerase in biochemical experiments, yet little is known about the specific genetic pathways involved in cellular remdesivir metabolism and cytotoxicity. Through genome-wide CRISPR/Cas9 screening (data not provided here) and RNA sequencing, we identify specific genes and pathways implicated in remdesivir metabolism. We show that remdesivir treatment leads to a global repression of mitochondrial respiratory activity. Further, we show that loss of the mitochondrial nucleoside transporter SLC29A3 or the mitochondrial adenylate kinase AK2 provide 10-72-fold mitigation of remdesivir toxicity while conserving its antiviral potency. This work provides candidate gene targets to reduce remdesivir toxicity and provides a proof-of-principle for the use of CRISPR/Cas9 screening to elucidate mechanisms of drug cytotoxicity.
|
|
|
Overall design |
RNA-sequencing of on liver and intestinal cell lines treated with remdesivir or Hydroxychloroquine (HCQ).
|
|
|
Contributor(s) |
Akinci E, Cha M, Hamilton MC, Lin L, Yeo GH, Bermudez-Cabrera HC, Zanetti LC, Velimirovic M, Khowpinitchai B, Fife JD, Sovrovic M, Jodhani R, Davey R, Cassa CA, Sherwood RI |
Citation(s) |
- Akinci E, Cha M, Lin L, Yeo G et al. Elucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR-Cas9 screening and transcriptomics. bioRxiv 2020 Aug 28. PMID: 32869031
|
|
Submission date |
Jul 22, 2020 |
Last update date |
Sep 08, 2020 |
Contact name |
Richard I Sherwood |
Organization name |
Brighan and Women's Hospital and Harvard Medical School
|
Department |
Division of Genetics, Department of Medicine
|
Street address |
77 Avenue Louis Pasteur
|
City |
Boston |
State/province |
MA |
ZIP/Postal code |
02115 |
Country |
USA |
|
|
Platforms (1) |
GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
Samples (24)
|
GSM4684608 |
HCT116, HCQ, 24h |
GSM4684609 |
HCT116, Remdesivir, 8h |
GSM4684610 |
HCT116, Remdesivir, 24h |
GSM4684611 |
HepG2, DMSO, 8h |
GSM4684612 |
HepG2, DMSO, 24h |
GSM4684613 |
HepG2, HCQ, 8h |
GSM4684614 |
HepG2, HCQ, 24h |
GSM4684615 |
HepG2, Remdesivir, 8h |
GSM4684616 |
HepG2, Remdesivir, 24h |
GSM4684617 |
HT29, DMSO, 8h |
GSM4684618 |
HT29, DMSO, 24h |
GSM4684619 |
HT29, HCQ, 8h |
GSM4684620 |
HT29, HCQ, 24h |
GSM4684621 |
HT29, Remdesivir, 8h |
GSM4684622 |
HT29, Remdesivir, 24h |
GSM4684623 |
PLC/PRF/5-Cas9NG-mChe, DMSO, 8h |
GSM4684624 |
PLC/PRF/5-Cas9NG-mChe, DMSO, 24h |
GSM4684625 |
PLC/PRF/5-Cas9NG-mChe, HCQ, 8h |
GSM4684626 |
PLC/PRF/5-Cas9NG-mChe, HCQ, 24h |
GSM4684627 |
PLC/PRF/5-Cas9NG-mChe, Remdesivir, 8h |
GSM4684628 |
PLC/PRF/5-Cas9NG-mChe, Remdesivir, 24h |
|
Relations |
BioProject |
PRJNA647903 |
SRA |
SRP273148 |
Supplementary file |
Size |
Download |
File type/resource |
GSE154936_raw_counts.csv.gz |
721.6 Kb |
(ftp)(http) |
CSV |
SRA Run Selector |
Raw data are available in SRA |
Processed data are available on Series record |
|
|
|
|
|